As controversy and coverage issues continue dragging uptake of available human papillomavirus (HPV) vaccines – the Centers for Disease Control and Prevention reported last week only a 3 percent increase since 2013 among the 13-to-17 age group – Antiva Biosciences Inc. is striding ahead with its direct-acting antiviral approach to HPV infections, thanks to $16 million in a series B financing.